July 30, 2026- The Healthcare Supply Chain Association (HSCA) and its traditional healthcare group purchasing organization (GPO) members commend the U.S. House Committee on Energy and Commerce for unanimously advancing two bipartisan bills that would expand patient access to lower-cost biosimilars: the Expedited Access to Biosimilars Act (H.R. 9661), led by Reps. Nick Langworthy (R-NY) and Kim Schrier (D-WA), and the Biosimilar Red Tape Elimination Act (H.R. 5526), led by Reps. August Pfluger (R-TX) and Greg Landsman (D-OH). This comes after the Senate Health, Education, Labor, and Pensions (HELP) Committee’s recent advancement of two companion bills, the Expedited Access to Biosimilars Act (S.1414), led by Sen. Rand Paul (R-KY), and the Biosimilars Red Tape Elimination Act (S.1954), led by Sens. Mike Lee (R-UT) and Ben Ray Lujan (D-NM).
The two bipartisan biosimilars bills that the Energy and Commerce Committee unanimously passed would remove barriers that slow biosimilar approval and adoption. The Expedited Access to Biosimilars Act would allow the FDA to approve a biosimilar without redundant studies when existing scientific evidence already demonstrates the product is safe and effective. The Biosimilar Red Tape Elimination Act would eliminate arbitrary regulatory distinctions between “biosimilar” and “interchangeable” designations, establishing a presumption that an approved biosimilar is interchangeable with its reference product without additional switching studies.